Table 3 Characteristics of antiretroviral treatment-naive HIV/HBV Co-infected patients with undetectable HBVDNA compared to those with detectable HBV DNA

Characteristic

HBV DNA < 20 IU/mL

HBV DNA ≥ 20 IU/mL

P-value T test

P-value Wilcoxon rank sum test

(N = 64)

(N = 88)

Mean (SD) age (years)

39.6 (8.0)

37.7 (10.4)

0.616

0.288

Mean (SD) weight (kg)

66.2 (9.5)

58.8 (13.4)

0.116

0.092

Mean (SD) BMI (kg/m2)

23.7 (4.9)

21.6 (4.4)

0.184

0.209

Mean (SD) CD4 count (cells/uL)

561.7 (504.5)

338.8 (302.7)

0.228

0.144

n (%)

n (%)

P-value Chi square

P-value Fisher

Male sex

4 (12.5 %)

28 (87.5 %)

0.701

0.728

Ethnicity

0.404

0.381

 Akan

6 (16.2 %)

31 (83.8 %)

 Ewe

0 (0.0 %)

15 (100.0 %)

 Ga

1 (12.5 %)

7 (87.5 %)

 Other

2 (9.5 %)

19 (90.5 %)

WHO HIV stage

0.265

0.174

 1 & 2

2 (5.1 %)

37 (94.9 %)

 3 & 4

7 (16.3 %)

36 (83.7 %)

HBeAg positive

0 (0.0 %)

19 (100.0 %)

0.083

0.110

HBeAb positive

9 (13.6 %)

57 (86.4 %)

0.107

0.193

HBeAg/E Ab combination

0.361

0.339

HBeAg positive/Ab negative

0 (0.0 %)

16 (100.0 %)

HBeAg negative/Ab positive

9 (14.3 %)

54 (85.7 %)

HBeAg negative/Ab negative

0 (0.0 %)

1 (100.0 %)

HBeAg positive/Ab positive

0 (0.0 %)

3 (100.0 %)

HBcIgM positive

0 (0.0 %)

1 (100.0 %)

0.726

1.000

Alanine aminotransferase

0.622

0.731

 Normal (5–40 U/L)

6 (12.2 %)

43 (87.8 %)

 Elevated > ULN

3 (8.8 %)

31 (91.2 %)

Aspartate aminotransferase

0.320

0.473

 Normal (5–50 U/L)

7 (13.5 %)

45 (86.5 %)

 Elevated > ULN

2 (6.5 %)

29 (93.6 %)

Albumin

0.945

1.000

 Normal (36–50 g/L)

4 (11.1 %)

42 (89.4 %)

 Low < LLN

5 (10.6 %)

19 (54.3 %)